Approved for BEQALZI (sonrotoclax) is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. (Accelerated approval based on response rate and durability of response.). Sonrotoclax is an inhibitor of B-cell lymphoma 2 (BCL-2) protein. Overexpression of…
Loading full data from Know Your Drugs Institute…